DrThomas George, Jr

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of narmafotinib in Combination with modified FOLFIRINOX in Pancreatic Cancer Patients

COMPENSATION AGREEMENT FOR PROTOCOL INCB177054-101

BillionToOne<>University of Florida GI Oncology Group Study Collaboration Proposal

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors

A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants with Gastrointestinal Cancers

A Single Arm Phase 4 Trial to Evaluate the Safety and Efficacy of Oral Fruquintinib in the Treatment of Refractory Metastatic Colorectal Cancer in Patients from Minority Populations Underrepresented in Prior Fruquintinib Studies

Implementation of Electronic Patient-Reported Outcomes Monitoring During Cancer Treatment: University of Florida Health System

A Phase II Platform Study to Evaluate Treatment with Cemiplimab Monotherapy or Cemiplimab plus Fianlimab or Other Novel Combinations in Patients with Colorectal Cancer with Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

Implementation of electronic patient-reported outcomes for symptom management in cancer patients

The Florida Summer Training in Research and Oncology for the Next Generation of Researchers (STRONGER) Program

An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Zeta Inhibitor (DGKzi) BAY 2965501 as Monotherapy, and in Combination, in Participants With Advanced Solid Tumors

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors

FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations

A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation

Safety, Pharmacokinetics (PK), and Efficacy of ONC-841 in Advanced Solid Tumors

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors (BiPAVE-001)

A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

Interaction between dietary taurine and microbiota sulfur metabolism in the development of colorectal cancer

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumor

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Understanding the Impact of Obesogenic Environments on the Incidence of Colorectal Cancer

UF Health Cancer Center Bridge Seed Grant (Continued)

A Multi-level Approach to Connecting Individuals to Cancer Clinical Research